Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL1876323

NC(=O)c1[nH]c2cnccc2c1-c1ccc(NC(=O)Nc2ccc(F)c(Cl)c2)cc1.O=C(O)C(F)(F)F

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2 P11137 5/20 0.53
MEN1 O00255 5/20 0.50
KMT2A Q03164 5/20 0.50
LMNA P02545 3/20 0.50
MAPT P10636 3/20 0.50
HTT P42858 3/20 0.47
TP53 P04637 1/20 0.47
KDR P35968 4/20 0.42
PDGFRB P09619 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 1/20 0.41
SLC2A1 P11166 1/20 0.41
CA2 P00918 1/20 0.41
RAF1 P04049 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
IDH2 P48735 1/20 0.39
KIT P10721 1/20 0.39
FLT3 P36888 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1880887 0.95 MEN1 (0.56) MAP2MEN1KMT2ALMNAMAPT
Trifluoroacetic Acid SCHEMBL1880747 0.90 MAP2 (0.55) MAP2MEN1KMT2ALMNAMAPT
SCHEMBL1876314 0.86 MAP2 (0.53) MAP2KDRPDGFRBIDH2KIT
Trifluoroacetic Acid SCHEMBL1880710 0.86 KDR (0.53) MAP2KDRPDGFRBKITFLT3
SCHEMBL1880281 0.85 MAP2 (0.53) MAP2KDRPDGFRBCA2RAF1
Trifluoroacetic Acid SCHEMBL1878628 0.84 MAP2 (0.53) MAP2MEN1KMT2ALMNAMAPT
Trifluoroacetic Acid SCHEMBL1883581 0.84 MAP2 (0.55) MAP2KMT2AKDRPDGFRBSMN1; SMN2
SCHEMBL4075062 0.84 MAP2 (0.63) MAP2MEN1KMT2ARAB9A
SCHEMBL1880291 0.83 MAP2 (0.59) MAP2MEN1KMT2ALMNAMAPT
Trifluoroacetic Acid SCHEMBL1880238 0.82 MAP2 (0.52) MAP2LMNAMAPTHTTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947706-B2 Anticancer agents; modulate kinases such as KDR (Kinase insert Domain Receptor and Tie-2 (TEK) , a member of the tyrosine kinase receptor family; 3-{4-[3-(2-methoxyphenyl)ureido]phenyl}-1H-pyrrolo[2,3-b]pyridine-2-carboxamide for example SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-05-24 US claimed
EP-1877409-B1 SUBSTITUTED PYRROLO-PYRIDINES, COMPOSITION CONTAINING THEM, METHOD FOR THEIR PRODUCING AND USE THEREOF AVENTIS PHARMA SA (FR) 2009-06-17 EP claimed
US-20080139606-A1 Substituted Pyrrolopyridines, Compositions Containing Them, Manufacturing Process Therefor and Use Thereof AVENTIS PHARMA S.A. (FR) 2008-06-12 US claimed
US-7947706-B2 Anticancer agents; modulate kinases such as KDR (Kinase insert Domain Receptor and Tie-2 (TEK) , a member of the tyrosine kinase receptor family; 3-{4-[3-(2-methoxyphenyl)ureido]phenyl}-1H-pyrrolo[2,3-b]pyridine-2-carboxamide for example SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-05-24 US disclosed
US-20080139606-A1 Substituted Pyrrolopyridines, Compositions Containing Them, Manufacturing Process Therefor and Use Thereof AVENTIS PHARMA S.A. (FR) 2008-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139606-A1 Substituted Pyrrolopyridines, Compositions Containing Them, Manufacturing Process Therefor and Use Thereof WEE1, CNKSR1, WEE2 MAP2 1477/4885MEN1 2890/4885KMT2A 2155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.